Clinical Trial

Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this study is to learn if bumetanide could alleviate the clinical symptoms in children with autism spectrum disorder (ASD), who has been predicted as high responders to bumetanide via a cytokine-based predictive model. The Eligible ASD participants identified as high responder to bumetanide will be randomly assigned to either the experimental group or the control group. Participants in the experimental group will receive bumetanide interventions, along with the behavioral interventions, for three months. Participants in the control group will only undergo behavioral interventions. The clinical symptoms and potential adverse effects will be closely monitored throughout the intervention period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-03; most recent amendment 2026-04-27.
Status change: Recruiting → Completed 2026-04-22
Status change: Not Yet Recruiting → Recruiting 2025-06-09
Trial Details
NCT Number NCT07005414
Lead Sponsor Fei Li
Conditions Autism Spectrum Disorder
Enrollment 66 participants
Start Date 2025-06-04
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-29